| Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity B Majumder, U Baraneedharan, S Thiyagarajan, P Radhakrishnan, ... Nature communications 6 (1), 6169, 2015 | 313 | 2015 |
| Bleomycin, neocarzinostatin and ionising radiation-induced bystander effects in normal diploid human lung fibroblasts, bone marrow mesenchymal stem cells, lung adenocarcinoma … M Chinnadurai, S Chidambaram, V Ganesan, U Baraneedharan, ... International journal of radiation biology 87 (7), 673-682, 2011 | 42 | 2011 |
| Radioprotective effect of DL-alpha-lipoic acid on mice skin fibroblasts. JR Davis GD, Masilamoni JG, Arul V, Kumar MS, Baraneedharan U, Paul SF ... Cell Biology Toxicology 25 (4), 331-340, 2009 | 40 | 2009 |
| Low dose short duration pulsed electromagnetic field effects on cultured human chondrocytes: An experimental study S Anbarasan, U Baraneedharan, SFD Paul, H Kaur, S Rangaswami, ... Indian journal of orthopaedics 50, 87-93, 2016 | 32 | 2016 |
| γ-H2AX assay: a technique to quantify DNA double strand breaks I Rakiman, M Chinnadurai, U Baraneedharan, SFD Paul, ... Adv Biotech, 39-41, 2008 | 28 | 2008 |
| Inhibition of rapamycin-induced AKT activation elicits differential antitumor response in head and neck cancers P Radhakrishnan, U Baraneedharan, S Veluchamy, M Dhandapani, ... Cancer research 73 (3), 1118-1127, 2013 | 26 | 2013 |
| Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun. 2015; 6: 6169 B Majumder, U Baraneedharan, S Thiyagarajan, P Radhakrishnan, ... Epub 2015/02/28. https://doi. org/10.1038/ncomms7169 PMID: 25721094, 0 | 6 | |
| Predicting tumor-immune response to checkpoint inhibitors using a novel patient-derived live tumor explant model. P Radhakrishnan, A Goldman, B Ulaganathan, A Thaya Kumar, ... Journal of Clinical Oncology 35 (15_suppl), e20035-e20035, 2017 | 4 | 2017 |
| Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity, Nat Commun 6: 6169, 2015 B Majumder, U Baraneedharan, S Thiyagarajan, P Radhakrishnan, ... Crossref, Medline, 0 | 2 | |
| A live tissue platform allows dynamic measurement of neovascularization and prediction of clinical response in human breast cancer samples, ex vivo M Smalley, N Alam, N Murmu, S Somashekhar, B Ulaganathan, ... Cancer Research 79 (4 Supplement), P6-07-03-P6-07-03, 2019 | 1 | 2019 |
| Nonuniform T-cell infiltration induced by PD-1 checkpoint blockade, ex vivo, predicts distinct clinical response M Smalley, B Shanthappa, H Gertje, M Lawson, B Ulaganathan, ... Cancer Research 78 (13_Supplement), 705-705, 2018 | 1 | 2018 |
| Case study: Non-uniform response to therapy in multiple metastatic is predicted using CANscriptTM, a live tissue, ex-vivo, platform C Ikpeazu, M Smalley, B Ulaganathan, A Thayakumar, L Majeiko, ... Cancer Research 78 (13 Supplement), LB-346-LB-346, 2018 | 1* | 2018 |
| Profiling metastatic lesions from a pembro-refractory patient to reveal distinct genomic instabilities and non-uniform response to drug combinations, ex vivo. C Ikpeazu, M Smalley, B Ulaganathan, A Thayakumar, S Basavaraja, ... Journal of Clinical Oncology 36 (15_suppl), e18021-e18021, 2018 | 1 | 2018 |
| Therapy-induced priming of natural killer cells predicts patient-specific tumor rejection in multiple breast cancer indications M Smalley, BU Shanthappa, H Gertje, M Lawson, B Ulaganathan, ... Cancer Research 78 (4 Supplement), P5-11-04-P5-11-04, 2018 | 1 | 2018 |
| Therapy-induced priming of natural killer cells predicts patient-specific tumor rejection in multiple breast cancer indications M Smalley, B Shanthappa, H Gertje, M Lawson, B Ulaganathan, ... Annals of Oncology 28 (suppl_11), mdx711. 010, 2017 | 1 | 2017 |
| Characterizing immunotherapy-induced lymphocyte infiltration at the single patient level using CANscriptTM, an ex-vivo human tumor model M Smalleyc, BU Shanthappa, H Gertje, M Lawson, B Ulaganathan, ... Immunotherapy of cancer 5, 2017 | 1 | 2017 |
| Current perspectives on velocardiofacial syndrome S Lakkakula, U Baraneedharan, BVKS Lakkakula Biomedical and Biotechnology Research Journal (BBRJ) 1 (2), 101-104, 2017 | 1 | 2017 |
| Identification of responders for Anti-CTLA4 in refractory colorectal cancers using CANScript™ platform B Majumder, B Ulaganathan, A Thayakumar, S Thiyagarajan, N Brijwani, ... Cancer Research 75 (15_Supplement), 1304-1304, 2015 | 1 | 2015 |
| Human tumor derived Oncoprint® platform predicts molecular mechanism of sensitivity and resistance to Fragmin in pancreatic cancer. M Sundaram, S Thiyagarajan, M Dhandapani, N Brijwani, A Prasath, ... Cancer Research 73 (8_Supplement), 5072-5072, 2013 | 1 | 2013 |
| PAT-1102, a novel HDAC inhibitor exhibits potent anti-tumor efficacy in patient-derived refractory solid tumors. P Radhakrishnan, M Dhandapani, B Ulaganathan, A Thayakumar, ... Cancer Research 73 (8_Supplement), 2051-2051, 2013 | 1 | 2013 |
